Clinical and translational advances in ovarian cancer therapy
PA Konstantinopoulos, UA Matulonis - Nature Cancer, 2023 - nature.com
Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …
is initially very responsive to platinum-based chemotherapy. However, the majority of …
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
PARP and PARG inhibitors in cancer treatment
D Slade - Genes & development, 2020 - genesdev.cshlp.org
Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …
genomic instability through radiotherapy and chemotherapy has been a powerful but …
State-of-the-art strategies for targeting the DNA damage response in cancer
Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …
damage response (DDR) and/or increased replication stress. These alterations promote the …
PARP inhibitor resistance: the underlying mechanisms and clinical implications
Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
A Marra, D Trapani, G Viale, C Criscitiello… - NPJ breast …, 2020 - nature.com
Triple-negative breast cancer (TNBC) is not a unique disease, encompassing multiple
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the
immunomodulatory effects of PARP inhibition have been incompletely studied. Here, we …
immunomodulatory effects of PARP inhibition have been incompletely studied. Here, we …
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
YZ Jiang, Y Liu, Y Xiao, X Hu, L Jiang, WJ Zuo, D Ma… - Cell research, 2021 - nature.com
Triple-negative breast cancer (TNBC) is a highly heterogeneous disease, and molecular
subtyping may result in improved diagnostic precision and targeted therapies. Our previous …
subtyping may result in improved diagnostic precision and targeted therapies. Our previous …
REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps
BRCA1/2 mutant tumor cells display an elevated mutation burden, the etiology of which
remains unclear. Here, we report that these cells accumulate ssDNA gaps and spontaneous …
remains unclear. Here, we report that these cells accumulate ssDNA gaps and spontaneous …
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Abstract ARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP
inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc …
inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc …